{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:44:46Z","timestamp":1783464286403,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["HTA NIHR132711"],"award-info":[{"award-number":["HTA NIHR132711"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rheumatoid arthritis is the commonest chronic inflammatory arthritis. Oral methotrexate is recommended as the first-line disease modifying drug for its management, and subcutaneous injections are typically prescribed if there is gastrointestinal intolerance or suboptimal efficacy. It is not known whether subcutaneous methotrexate is more effective and cost-effective compared to oral methotrexate when used as first-line treatment in people diagnosed with rheumatoid arthritis. The Methotrexate Oral Or SubcutanEous (MOOSE) trial aims to compare the clinical and cost-effectiveness of subcutaneous and oral methotrexate when used as first-line disease modifying anti-rheumatic drug in adults with rheumatoid arthritis and collect information about the acceptability of both routes of administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MOOSE is an open-label, multi-centre, assessor-blinded, two-arm randomised controlled trial, with an internal feasibility assessment, economic evaluation and qualitative study. It is a secondary care-based trial, involving NHS hospital rheumatology clinics. Potentially eligible patients will be approached to participate around the time of their initial clinic visit. Eligible patients who consent will be randomised to either oral or subcutaneous methotrexate. Randomisation will be minimised by trial centre, 28-joint disease activity score, and disease duration. Interventions will be prescribed open-label with participants and clinicians aware of treatment allocated. Outcome assessors will be blinded to treatment allocation. Each participant will be in the trial for 52\u00a0weeks. The primary outcome is remission assessed at 24\u00a0weeks. Secondary outcomes include disease activity, quality of life, mental health and employment. A qualitative study will involve semi-structured interviews to analyse the acceptability of interventions. The health economic study will use healthcare utilisation data, quality of life data, and cost-estimates to model cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Whether to use subcutaneous or oral methotrexate first line for RA is an important question for patients and clinicians. MOOSE study will provide evidence on the clinical and cost-effectiveness of oral and subcutaneous routes of methotrexate administration to answer this important question.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Prospectively registered with the International Standard Randomised Controlled Trial Number (ISRCTN) 14,403,521. Registered on 03 August 2023\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN14403521\" ext-link-type=\"uri\">https:\/\/doi.org\/10.1186\/ISRCTN14403521<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09020-4","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:21:23Z","timestamp":1762957283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Methotrexate oral or subcutaneous for rheumatoid arthritis (MOOSE): study protocol for a multi-centre randomised trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Sarah","family":"McClure","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Haydock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Rick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Jinks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trish","family":"Hepburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"5","key":"9020_CR1","first-page":"736","volume":"56","author":"A Abhishek","year":"2017","unstructured":"Abhishek A, et al. Rheumatoid arthritis is getting less frequent-results of a nationwide population-based cohort study. Rheumatology (Oxford). 2017;56(5):736\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"9020_CR2","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1002\/art.27692","volume":"62","author":"MP van der Linden","year":"2010","unstructured":"van der Linden MP, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537\u201346.","journal-title":"Arthritis Rheum"},{"key":"9020_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001603","author":"CJ Edwards","year":"2012","unstructured":"Edwards CJ, et al. Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study. BMJ Open. 2012. https:\/\/doi.org\/10.1136\/bmjopen-2012-001603.","journal-title":"BMJ Open"},{"issue":"1","key":"9020_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J Braun","year":"2008","unstructured":"Braun J, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73\u201381.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"9020_CR5","first-page":"483","volume":"22","author":"MS Islam","year":"2013","unstructured":"Islam MS, et al. Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis. Mymensingh Med J. 2013;22(3):483\u20138.","journal-title":"Mymensingh Med J"},{"issue":"5","key":"9020_CR6","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/1756-185X.12910","volume":"21","author":"P Dhaon","year":"2018","unstructured":"Dhaon P, et al. Oral methotrexate in split dose weekly versus oral or parenteral methotrexate once weekly in rheumatoid arthritis: a short-term study. Int J Rheum Dis. 2018;21(5):1010\u20137.","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"9020_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221823","volume":"14","author":"AM Bujor","year":"2019","unstructured":"Bujor AM, et al. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS One. 2019;14(9): e0221823.","journal-title":"PLoS One"},{"issue":"8","key":"9020_CR8","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses >\/=15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73(8):1549\u201351.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9020_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","volume":"75","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1003\u20138.","journal-title":"Ann Rheum Dis"},{"key":"9020_CR10","unstructured":"The British National Formulary database. https:\/\/bnf.nice.org.uk\/drugs\/methotrexate\/medicinal-forms\/. Accessed 27 Apr 2025."},{"issue":"9","key":"9020_CR11","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"9020_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88.","journal-title":"BMC Health Serv Res"},{"key":"9020_CR13","unstructured":"NICE health technology evaluations: the manual (PMG36) Published: 31 January 2022 Last updated: 31 October 2023."},{"issue":"4","key":"9020_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/annrheumdis-2019-216539","volume":"79","author":"P Emery","year":"2020","unstructured":"Emery P, et al. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the vedera trial. Ann Rheum Dis. 2020;79(4):464\u201371.","journal-title":"Ann Rheum Dis"},{"key":"9020_CR15","unstructured":"Ritchie JSL, Analysing qualitative data, in Analysing qualitative data, A.B. Bryman, R. G, Editor. 1994, Routledge. 246."},{"key":"9020_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-117","author":"NK Gale","year":"2013","unstructured":"Gale NK, et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013. https:\/\/doi.org\/10.1186\/1471-2288-13-117.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"9020_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1558689812474372","volume":"7","author":"VL Plano Clark","year":"2013","unstructured":"Plano Clark VL, et al. Practices for embedding an interpretive qualitative approach within a randomized clinical trial. J Mixed Methods Res. 2013;7(3):219\u201342.","journal-title":"J Mixed Methods Res"},{"key":"9020_CR18","unstructured":"Saldana J, Longitudinal qualitative research: Analyzing change through time. 2023: RowmanAltamira."},{"issue":"4\u20135","key":"9020_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1080\/10503300802621180","volume":"19","author":"HJ Schielke","year":"2009","unstructured":"Schielke HJ, et al. Creative consensus on interpretations of qualitative data: the Ward method. Psychother Res. 2009;19(4\u20135):558\u201365.","journal-title":"Psychother Res"},{"issue":"298","key":"9020_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/01621459.1962.10480664","volume":"57","author":"A Zellner","year":"1962","unstructured":"Zellner A. An efficient method of estimating seemingly unrelated regressions and tests for aggregation bias. J Am Stat Assoc. 1962;57(298):348\u20130.","journal-title":"J Am Stat Assoc"},{"issue":"12","key":"9020_CR21","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s40273-018-0697-3","volume":"36","author":"AJ Hatswell","year":"2018","unstructured":"Hatswell AJ, et al. Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36(12):1421\u20136.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"9020_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/hec.1161","volume":"16","author":"S Eckermann","year":"2007","unstructured":"Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16(2):195\u2013209.","journal-title":"Health Econ"},{"issue":"3","key":"9020_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0272989X13505910","volume":"34","author":"M Strong","year":"2014","unstructured":"Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach. Med Decis Making. 2014;34(3):311\u201326.","journal-title":"Med Decis Making"},{"issue":"11","key":"9020_CR24","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/ard.2007.071092","volume":"66","author":"SM Verstappen","year":"2007","unstructured":"Verstappen SM, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09020-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09020-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09020-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:21:25Z","timestamp":1762957285000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09020-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9020"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09020-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted by the South Central\u2014Berkshire Research Ethics Committee 2nd August 2023. Substantial amendment 01 was an administrative change approved 22nd August 2023. Substantial amendment 02 included a protocol update to version 2.0, main changes were the addition of prescription guidance to clarify that prescription can be issued by primary care via shared care agreement and change of the SWAT primary outcome from patients randomised to patients consented. This amendment also included a new patient letter\/email for sending vouchers and was approved 5th July 2024. Substantial amendment 03 included a new advertising postcard and poster update and was approved 1\u2009st Nov 2024.The process for obtaining participant informed consent will be in accordance with the REC guidance, and GCP and any other regulatory requirements that might be introduced. The investigator or their nominee and the participant shall both sign and date the Consent Form before the person can participate in the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable, no identifying images or personal or clinical details of participants are presented here or will be presented in the trial results. Informed consent materials are available from the author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors and PIs declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"495"}}